Sun Pharmaceutical Industries, Inc.
Clinical Trials
7
Trial Phases
3 Phases
Drug Approvals
240
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 24
- Next
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
- Conditions
- Actinic Keratosis
- Interventions
- Drug: Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Other: VehicleDevice: Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E.
- First Posted Date
- 2025-08-28
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- Sun Pharmaceutical Industries, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT07144852
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
- Conditions
- Actinic Keratosis
- Interventions
- Drug: Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Other: Vehicle containing excipients only (VEH) without active ingredientDevice: Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E
- First Posted Date
- 2025-08-27
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- Sun Pharmaceutical Industries, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT07144345
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
- First Posted Date
- 2025-08-21
- Last Posted Date
- 2025-08-21
- Lead Sponsor
- Sun Pharmaceutical Industries, Inc.
- Target Recruit Count
- 355
- Registration Number
- NCT07133308
- Locations
- 🇺🇸
Total Skin And Beauty Dermatology Center, Birmingham, Alabama, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
🇺🇸Paradigm Clinical Research - San Diego, San Diego, California, United States
European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Sun Pharmaceutical Industries, Inc.
- Target Recruit Count
- 407
- Registration Number
- NCT05041803
- Locations
- 🇫🇷
Service de Dermatologie CHRU de Brest - Hopital Morvan, Brest Cedex, Finistere, France
🇫🇷Service de Dermatologie Centre Hospitalier Universitaire de Nice - Hopital Archet 2, Nice, Provence-Alpes-Cote d'Azur, France
🇫🇷CHU de Bordeaux, Hopital Saint-Andre, Bordeaux, France
News
Sun Pharma Discontinues Psoriasis and Eczema Drug SCD-044 After Phase 2 Trial Failures
Sun Pharma's experimental oral drug SCD-044 (Vibozilimod) failed to meet primary endpoints in Phase 2 trials for both psoriasis and atopic dermatitis, missing the 75% improvement target in PASI and EASI scores at 16 weeks.